INTEGRATE 2B
30 Nov 2021
Trial Summary
A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Acronym:
INTEGRATE 2B
ACTRN/NCT /ethics:
ACTRN12616000420448
Scientific title:
Randomised Phase III Controlled Trials of Regorafenib containing regimens versus standard care in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Sponsor / Cooperative group:
Bayer HealthCare Pharmaceuticals Inc
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Advanced Gastro-Oesophageal Cancer |
| Cancer Stage | Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2016-11-06 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| Stella.Papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Timothy Price |
| Recruitment Status | Recruiting |